The results demonstrate that HSPA4 expression is higher in responders compared with non-responders, suggesting that HSPA4 upregulation might be a potential biomarker for predicting better responses to the combined therapy in patients with GC. The gene discussed is HSPA4; the disease is gastric cancer.